Shape What’s Next in Molecular Pathology
Discover, connect, and innovate with Agilent at the AMP 2025 conference! This year, we're bringing together world-class experts, breakthrough technologies, and groundbreaking research to tackle the field's most critical challenges. Connect with industry leaders, innovators, and peers who are shaping the next era of molecular profiling.
New Product Introductions
SureSelect Cancer Pan Heme Assay
-
Coming Soon!
SureSelect Cancer Pan Heme Assay is a hybrid capture-based NGS assay that interrogates both DNA and RNA to deliver comprehensive genomic profiling for hematologic malignancies. The assay was curated and independently validated by leading hematology experts at Roswell Park Comprehensive Cancer Center.*
High Sensitivity Genomic DNA ScreenTape Analysis
-
New!
The Agilent High Sensitivity Genomic DNA ScreenTape assay expands the capabilities of the TapeStation platform by enabling reliable analysis of low concentration gDNA samples. This assay demonstrates robust performance across a broad dynamic range, with a lower detection limit of 20 pg/µL and a functional DNA Integrity Number (DIN) range beginning at 0.25 ng/µL.*
MMR IHC Panel pharmDx
-
New!
MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify mismatch repair deficient (dMMR) colorectal cancer (CRC) patients eligible for treatment with OPDIVO® (nivolumab) alone or OPDIVO (nivolumab) in combination with YERVOY® (ipilimumab).**
